Neurology
Neurodegenerative Disease
12
Pipeline Programs↗
8
Active Trials↗
6
Companies Involved↗
Neurodegenerative Disease is an emerging landscape with 12 programs across 6 companies. The most active players are Novabio Therapeutics, Johnson & Johnson, Eisai. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 24
Phase 3
No programs
Analysis
Trial Status
20
clinical trials
Completed7 · 35%
Recruiting5 · 25%
Unknown status4 · 20%
Not yet recruiting2 · 10%
Enrolling by invitation1 · 5%
Terminated1 · 5%
Clinical Trials
Trial Activity
20 trials
3D Printers for Autonomy in the Care of Inpatients in Continuing and Rehabilitation Care
Recruiting·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·Preclinical·NCT07087574·75 enrolled
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
Completed·—·Phase 2·NCT02656498·135 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)